menu
    • menu
    [{"orgOrder":0,"company":"Pharmtechnology","sponsor":"ClinPharmInvest","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELARUS","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Torsemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmtechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmtechnology \/ ClinPharmInvest","highestDevelopmentStatusID":"6","companyTruncated":"Pharmtechnology \/ ClinPharmInvest"},{"orgOrder":0,"company":"Ferrer Internacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Torsemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Ferrer Internacional","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ferrer Internacional \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ferrer Internacional \/ Undisclosed"},{"orgOrder":0,"company":"Sarfez Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Torsemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sarfez Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Sarfez Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sarfez Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sarfez Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Torsemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sarfez Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Sarfez Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sarfez Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sarfez Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Torsemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sarfez Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Sarfez Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sarfez Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sarfez Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Torsemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sarfez Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Sarfez Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sarfez Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sarfez Pharmaceuticals","sponsor":"Novo Integrated Sciences","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Torsemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sarfez Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Sarfez Pharmaceuticals \/ Novo Integrated Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Sarfez Pharmaceuticals \/ Novo Integrated Sciences"},{"orgOrder":0,"company":"Sarfez Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Torsemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Undisclosed","graph2":"Phase III","graph3":"Sarfez Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sarfez Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sarfez Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sarfez Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Torsemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Undisclosed","graph2":"Phase III","graph3":"Sarfez Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sarfez Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sarfez Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sarfez Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Torsemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Sarfez Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Sarfez Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sarfez Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sarfez Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Torsemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Undisclosed","graph2":"Phase III","graph3":"Sarfez Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sarfez Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sarfez Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sarfez Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Torsemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Undisclosed","graph2":"Phase III","graph3":"Sarfez Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sarfez Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sarfez Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sarfez Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Torsemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Undisclosed","graph2":"Phase III","graph3":"Sarfez Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sarfez Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sarfez Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Torsemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Berlin Chemie","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Berlin Chemie \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Berlin Chemie \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for DSSTox_CID_3690

    Menu

    DSSTox_CID_3690

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Berlin Chemie

                            Germany arrow
                            SupplySide West
                            Not Confirmed

                            Berlin Chemie

                            Germany arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Comparative Bioavailability Study of Two Torasemide 10 mg Tablets Formulations in Healthy Adult Participants...

                            Details : Torsemide is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 01, 2025

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sarfez Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Sarfez Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone

                            Details : Torsemide is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of unspecified medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 02, 2025

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sarfez Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Sarfez Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Torsemide + Spironolactone ER FDC: Food Effect On Bioavailability In Healthy Adults

                            Details : Torsemide is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of unspecified medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 29, 2025

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sarfez Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Sarfez Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioavailability & Bioequivalence of ER Torsemide & Spironolactone FDC in Healthy Subjects

                            Details : Torsemide is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of unspecified medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 11, 2025

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sarfez Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Sarfez Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of ER Torsemide & IR Torsemide in Patients with Heart Failure

                            Details : Torsemide is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 29, 2025

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sarfez Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Sarfez Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Crossover Study of Patients with HF to Compare Natriuretic Effects of IR Torsemide Vs. ER Torsemide Over 12 ...

                            Details : Torsemide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 27, 2024

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sarfez Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Sarfez Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder

                            Details : Torsemide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 16, 2024

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sarfez Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Sarfez Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal

                            Details : Torsemide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 20, 2023

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sarfez Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Sarfez Pharmaceuticals

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Novo Integrated Sciences

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Consulting Agreement with Ph...

                            Details : Sarfez’s FDA-approved, once-a-day novel formulation of loop diuretic torsemide, SOAANZ®, provides a new treatment option for patients suffering from heart failure who experience persistent edema or swelling in the lower limbs and/or abdomen.

                            Product Name : Soaanz

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 30, 2022

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Novo Integrated Sciences

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Pharmtechnology

                            Belarus arrow
                            SupplySide West
                            Not Confirmed

                            Pharmtechnology

                            Belarus arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : ClinPharmInvest

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Two Formulations of Torasemide Tablet 10 mg in Healthy Volunteers Under Fasting Condit...

                            Details : Torasemide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 10, 2021

                            Lead Product(s) : Torsemide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : ClinPharmInvest

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth